Author:
Hill Kevin D.,Henderson Heather T.,Hornik Christoph P.,Li Jennifer S.
Abstract
AbstractRecent regulatory initiatives in the United States of America and Europe have transformed the paediatric clinical trials landscape by significantly increasing capital investment and paediatric trial volume. The purpose of this manuscript was to review the impact of these initiatives on the paediatric cardiovascular trials landscape when compared with other paediatric sub-specialties. We also evaluate factors that may have contributed to the success or failure of recent major paediatric cardiovascular trials so as to inform the optimal design and conduct of future trials in the field.
Publisher
Cambridge University Press (CUP)
Subject
Cardiology and Cardiovascular Medicine,General Medicine,Pediatrics, Perinatology, and Child Health
Reference34 articles.
1. European Medicines Agency. Assessment Report for Revatio. Retrieved December 26, 2014, from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000638/WC500107804.pdf
2. Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia
3. Food and Drug Administration. Status Report to Congress on the Pediatric Exclusivity Provision, 2001. Retrieved December 30, 2014, from http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm049915.pdf
4. Single-Dose Pharmacokinetics of Sotalol in a Pediatric Population with Supraventricular and/or Ventricular Tachyarrhythmia
5. STARTS-2
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献